MacroGenics Q2 10-Q: $52.8M Royalty Extinguishment Loss, $86.1M CDMO Sale Gain, and New Insider Trading Plans

summarizeSummary

MacroGenics filed its Q2 10-Q, revealing a $52.8M non-cash loss from amending its royalty deal, an $86.1M gain from selling its CDMO business, and new insider trading plans for up to 1.24M shares.

check_boxKey Events · Earnings and Guidance · MGNX

• Royalty Deal Amendment Triggers $52.8M Loss

  The company recognized a $52.8M non-cash loss on extinguishment of its royalty monetization liability after amending its agreement with Sagard, which increased the purchase price to $130M and redefined the threshold amount.

• CDMO Sale Generates $86.1M Net Gain

  The sale of the CDMO operations to Bora closed on June 30, 2026, resulting in a net gain of $86.1M after transaction costs, with $119.6M in cash received in July 2026.

• Insider Trading Plans Cover 1.24M Shares

  CFO James Karrels, General Counsel Jeffrey Peters, and Controller Beth Smith adopted 10b5-1 plans covering up to 613,207, 587,875, and 44,000 shares respectively, with first trades possible starting August 19, 2026.

• Cash Runway Extended Through 2028

  Management reiterated that cash, equivalents, and marketable securities of $173.3M as of June 30, 2026, plus the $119.6M from Bora, $24.5M from Sanofi, and $10M from Gilead, support operations through 2028.

auto_awesomeAnalysis · MGNX · Life Sciences

The 10-Q provides the full financial picture behind the Q2 earnings release. The $52.8M loss on extinguishment of the royalty monetization liability is a non-cash accounting charge from amending the Sagard agreement, while the $86.1M net gain on the CDMO sale is a one-time boost. More importantly, three senior executives adopted 10b5-1 plans covering up to 1.24M shares, creating a potential overhang on the stock.